Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Autologous stem cell therapy has been shown to be effective in patients with systemic
sclerosis. Nevertheless treatment is associated with treatment related mortality and patients
die during follow up despite successful transplantation.
Intention of this trial is to improve overall survival by modifying the existing protocol
used for the ASTIS trial.
To reduce treatment toxicity we reduce the dose of Cyclophosphamide (CYC) for mobilisation to
2x1g.
Especially in patients with cardiac manifestations we also modify the conditioning regimen by
adding thiotepa and reducing CYC; as CYC has known cardiotoxic side effects.